T Cell News and Research

Latest T Cell News and Research

New study investigates Ebola protein

A new study by Robert Stahelin, an adjunct associate professor of chemistry and biochemistry at the University of Notre Dame and an associate professor at the Indiana University School of Medicine-South Bend, as well as a member of Notre Dame's Eck Institute for Global Health, investigates how the most abundant protein that composes the Ebola virus, VP 40, mediates replication of a new viral particle.

11 Dec 2014

New technique allows rapid, large-scale studies of gene function

Using a gene-editing system originally developed to delete specific genes, MIT researchers have now shown that they can reliably turn on any gene of their choosing in living cells.

11 Dec 2014

NYSCF, CMTA partner to advance research on genetic neuropathies

The New York Stem Cell Foundation Research Institute, a non-profit organization dedicated to accelerating cures through stem cell research, announced a collaboration today with the Charcot-Marie-Tooth Association, a patient-led disease foundation with the mission to advance research on genetic neuropathies that leads to the development of new therapies.

11 Dec 2014

Potential new active substances for treating dengue virus

Researchers from Johannes Gutenberg University Mainz and the Julius Maximilian University of Würzburg are proposing potential new active substances for treating the dengue virus. Just like Ebola, dengue fever is also caused by a virus for which there is currently no cure and no vaccine and can be fatal.

11 Dec 2014

Johns Hopkins study shows gene expression in autism brains

While many different combinations of genetic traits can cause autism, brains affected by autism share a pattern of ramped-up immune responses, an analysis of data from autopsied human brains reveals. The study, a collaborative effort between Johns Hopkins and the University of Alabama at Birmingham, included data from 72 autism and control brains.

11 Dec 2014

Silvia Jurisson recognized as AAAS Fellow for contributions to cancer research

Nuclear medicine is the branch of medicine that uses radioactive materials to provide diagnostics and treatments for cancer. Often, standard protocols involve using radioactive isotopes developed to image as well as weaken cancer cells in the body. With more than 30 years of research in radiopharmaceutical chemistry, Silvia Jurisson, a researcher at the University of Missouri, is a world-renowned scientist who continues to develop breakthrough materials used in the detection and treatment of cancer.

11 Dec 2014

$Using Refractory Metals in Cancer Treatments$

Using Refractory Metals in Cancer Treatments

This interview discusses how refractory metals can be used in cancer treatments.

From H.C. Starck Solutions 10 Dec 2014

Carboplatin and paclitaxel show promise for advanced thymic carcinoma

A multicentre, phase II study of carboplatin and paclitaxel in chemotherapy-naïve patients with advanced thymic carcinoma has shown that the treatment has promising efficacy compared with standard anthracycline-based chemotherapy.

10 Dec 2014

PD-L1 expression tied to favourable prognosis in SCLC

Programmed death-ligand 1 is expressed by around 70% of small-cell lung cancers and is associated with favourable patient outcomes, Japanese researchers report.

10 Dec 2014

Scientists develop new technique to get detailed images of mouse neurons

Scientists can now explore nerves in mice in much greater detail than ever before, thanks to an approach developed by scientists at the European Molecular Biology Laboratory in Monterotondo, Italy. The work, published online today in Nature Methods, enables researchers to easily use artificial tags, broadening the range of what they can study and vastly increasing image resolution.

10 Dec 2014

Variations in ERAP1 enzyme could lead to Ankylosing Spondylitis

Scientists at the University of Southampton have discovered variations in an enzyme belonging to the immune system that leaves individuals susceptible to Ankylosing Spondylitis.

10 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

UT Southwestern biophysicist named recipient of 2015 Edith and Peter O'Donnell Award in Science

The Academy of Medicine, Engineering and Science of Texas has selected Dr. Yuh Min Chook, Professor of Pharmacology and of Biophysics at UT Southwestern Medical Center, as the recipient of the 2015 Edith and Peter O'Donnell Award in Science.

10 Dec 2014

Chemical chaperone: A new therapeutic option for epilepsy

Researchers found out that the conformational defect in a specific protein causes Autosomal Dominant Lateral Temporal Lobe Epilepsy (ADLTE) which is a form of familial epilepsy. They showed that treatment with chemical corrector called "chemical chaperone" ameliorates increased seizure susceptibility in a mouse model of human epilepsy by correcting the conformational defect.

10 Dec 2014

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation.

10 Dec 2014

Southern Regional Education Board honors UTSA professor as Mentor of the Year

Edwin Barea-Rodriguez, professor and chair of the UTSA Department of Biology, was recently honored as the Mentor of the Year by the Southern Regional Education Board at a conference in Atlanta. More than 1,300 attended the conference, where the nation's largest gathering of minority doctoral scholars discussed issues facing new and aspiring faculty members.

10 Dec 2014

University of Illinois study could provide insight into protein-misfolding diseases

When a large protein unfolds in transit through a cell, it slows down and can get stuck in traffic. Using a specialized microscope -- a sort of cellular traffic camera -- University of Illinois chemists now can watch the way the unfolded protein diffuses.

10 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT).

10 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014